ClinicalTrials.gg
CompletedNCT05603182Updated Mar 7, 2024

A Study of PRA052 in Healthy Volunteers

A Phase 1 interventional study of PRA052 and Placebo in Healthy, sponsored by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-07.

Sponsored by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PRA052 in healthy volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 6 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.

First submitted before Prometheus Biosciences, Inc. became part of Merck & Co., Inc.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female (of non- only) between minimum adult legal age (according to local laws for signing the document) and 60 years of age.
  • Male subjects must use reliable forms of during sexual intercourse with female partners from screening to 12 weeks after the end of dosing.
  • Good general health as determined by medical history, and by results of physical examination, chest x-ray, vital signs, , and clinical laboratory tests obtained within 28 days (4 weeks) prior to study drug administration

Exclusion criteria

Exclusion Criteria:

  • History or presence of any organ system disease that could interfere with the objectives of the study or the safety of the subjects.
  • Blood pressure and heart rate are outside the ranges 90-140 mmHg systolic, 40-90 mmHg diastolic, heart rate 40-99 beats/min.
  • 12-lead with any abnormality judged by the Investigator to be clinically significant, QRS >= 120 milliseconds (msec), or interval of > 450 msec for men or >470 msec for women.
  • Presence or history of any abnormality or illness, which in the opinion of the Investigator may affect absorption, distribution, metabolism or elimination of the study drug.
  • Any screening laboratory evaluation outside the laboratory reference range that is judged by the Investigator to be clinically significant.
  • History of or current active tuberculosis (TB) infection; history of latent TB that has not been fully treated or current latent TB infection as indicated by a positive QuantiFERON-TB test.
  • History of significant allergy to any medication as judged by the Investigator.
  • History of alcohol or drug abuse within the past 24 months.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    SAD Cohorts 1-8 Experimental Arm

    Subjects will receive a single intravenous or subcutaneous dose of PRA052 in a dose escalation format

    Drug: PRA052

  • Placebo comparator
    SAD Cohorts 1-8 Placebo Arm

    Subjects will receive a single intravenous or subcutaneous dose of placebo

    Other: Placebo

  • Experimental
    MAD Cohorts 1-5 Experimental Arm

    Subjects will receive three subcutaneous or intravenous doses of PRA052, one dose every 2 weeks, in a dose escalation format

    Drug: PRA052

  • Placebo comparator
    MAD Cohorts 1-5 Placebo Arm

    Subjects will receive three subcutaneous or intravenous doses of placebo, one dose every 2 weeks

    Other: Placebo

Interventions

  • DrugPRA052

    PRA052

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Treatment emergent adverse events

    Incidence, severity, and causal relationship of TEAEs

    Time frame: Up to 20 weeks

Secondary outcomes

  1. Cmax

    Maximum concentration after single and multiple ascending doses

    Time frame: Up to 20 weeks

  2. Tmax

    Time to reach maximum concentration after single and multiple ascending doses

    Time frame: Up to 20 weeks

  3. t1/2

    Half life after single and multiple ascending doses

    Time frame: Up to 20 weeks

  4. F%

    Bioavailability after SC injection

    Time frame: Up to 20 weeks

  5. ADA

    Incidence of anti-drug antibody after single and multiple ascending doses

    Time frame: Up to 20 weeks

07

Study locations

1 site
  • Prometheus Clinical Site
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Feb 2024, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2022
First posted
Nov 2, 2022
StartActual
Nov 7, 2022
Primary completionActual
Feb 21, 2024
CompletionActual
Feb 21, 2024
Last update
Mar 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05603182
Responsible party
Sponsor
First posted
Nov 2, 2022
Start date
Nov 7, 2022
Primary completion
Feb 21, 2024
Completion
Feb 21, 2024
Last update
Mar 7, 2024

Study contacts

Prometheus Biosciences, Inc.
study chair · Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion